当前位置:首页>产品中心>单抗/多抗>Anti-Human methamphetamine Reference Antibody|抗人甲基苯丙胺参考抗体(靶标:甲基苯丙胺)

Anti-Human methamphetamine Reference Antibody|抗人甲基苯丙胺参考抗体(靶标:甲基苯丙胺)

  • 货号:RB9THP065016
  • 价格:面议
  • 点击:535
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG2-kappa
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性General
靶标(+)-methamphetamine
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号537-46-2
背景信息Devextinetug (IXT-M200) is a chimeric anti-methamphetamine, mouse-derived IgG2κ antibody.
• Methamphetamine Use and Cardiovascular Disease., PMID:31433698
• Methamphetamine deaths: Changing trends and diagnostic issues., PMID:33423599
• Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review., PMID:34166684
• Methamphetamine-associated catatonia: Case series and systematic review of the literature from 1943-2020., PMID:37459499
• Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation?, PMID:34780869
• Zinc reduces the detection of cocaine, methamphetamine, and THC by ELISA urine testing., PMID:21740689
• Household Contamination with Methamphetamine: Knowledge and Uncertainties., PMID:31771211
• A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy., PMID:35157254
• Methamphetamine-induced toxicity: The role of autophagy?, PMID:27746146
• Mandatory treatment for methamphetamine use in Australia., PMID:33836785
别名CAS: 2609642-90-0
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 740
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 868
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 718
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 603
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 793
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 764
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 759
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 754
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 605
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 602
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 930
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 816
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 824
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 818
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 547
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 768
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 953
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1013
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 923
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 838
总计 33037 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30